Estrella Immunopharma, Inc. (ESLA) vs Lipocine Inc. (LPCN)
A side-by-side comparison of Estrella Immunopharma, Inc. and Lipocine Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ESLA
Estrella Immunopharma, Inc.
$0.46HealthcareDelayed quote: Oct 6, 2026, 12:53 PM EDT
LPCN
Lipocine Inc.
$2.09HealthcareDelayed quote: Oct 6, 2026, 12:48 PM EDT
Total return — ESLA vs LPCN
growth of $100 · dividends reinvested · last 5yESLA -95.5% (-46.2%/yr)LPCN -90.3% (-37.2%/yr)LPCN compounded faster over this window
ESLA LPCN
ESLA vs LPCN: by the numbers
- •ESLA is the larger company ($20M vs $17M market cap).
- •Both run net losses; ESLA's is the smaller (0.00% vs -755.13% net margin).
Metrics side by side
Valuation
| Metric | ESLA | LPCN |
|---|---|---|
| P/S ratio | N/A | 10.98 |
| P/B ratio | N/A | 0.79 |
Profitability
| Metric | ESLA | LPCN |
|---|---|---|
| Gross margin | 0.00% | -334.26% |
| Operating margin | 0.00% | -524.69% |
| Net margin | 0.00% | -755.13% |
| ROE | N/A | -54.45% |
| ROIC | N/A | -57.74% |
Growth (annualized)
| Metric | ESLA | LPCN |
|---|---|---|
| Total return CAGR (5Y) | -46.34% | -34.76% |
Frequently asked
- How have ESLA and LPCN total returns compared?
- Over the past 5 years, ESLA delivered -46.34% and LPCN delivered -34.76% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.